Our results suggest that CHEK2 truncating mutations confer a 3-fold (p = 0.001) increased risk of DCIS and a missense c.470T > C variant confers lower risk (OR = 1.5, p = 0.04). The gene discussed is CHEK2; the disease is ductal breast carcinoma in situ.